Role and Efficacy of Sentinel Lymph Node Biopsy in Oral Cavity Squamous Cell Carcinoma

  • Steven B. Chinn
  • Stephen Y. LaiEmail author
Part of the Difficult Decisions in Surgery: An Evidence-Based Approach book series (DDSURGERY)


Oral cavity squamous cell carcinoma (OCSCC) is diagnosed in over 32,000 patients and associated with over 7000 deaths annually [1]. Despite advances in surgical, reconstructive and adjuvant therapy, 5-year overall survival remains at 60% [2]. Surgical resection of the primary tumor is the standard treatment for local control. Management of the neck traditionally was based on presence of clinical adenopathy (cN+) or clinically negative nodes (cN0). Neck dissection is and remains the standard first line regional therapy for cN+ disease in OCSCC [2]. Over the last 2 decades there has been a transition from the “Halstedian” approach to resection with de-escalation from radical neck dissection to modified radical neck dissection to selective neck dissection without a decrease of regional control and improved functional outcomes and quality of life [3].


  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. Epub 2017/01/06. PubMed PMID: 28055103.CrossRefPubMedGoogle Scholar
  2. 2.
    Chinn SB, Myers JN. Oral cavity carcinoma: current management, controversies, and future directions. J Clin Oncol. 2015;33(29):3269–76. PubMed PMID: 26351335; PMCID: PMC5320919.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Clayman GL, Frank DK. Selective neck dissection of anatomically appropriate levels is as efficacious as modified radical neck dissection for elective treatment of the clinically negative neck in patients with squamous cell carcinoma of the upper respiratory and digestive tracts. Arch Otolaryngol Head Neck Surg. 1998;124(3):348–52. Epub 1998/04/03. PubMed PMID: 9525524.CrossRefGoogle Scholar
  4. 4.
    Weiss MH, Harrison LB, Isaacs RS. Use of decision analysis in planning a management strategy for the stage N0 neck. Arch Otolaryngol Head Neck Surg. 1994;120(7):699–702. Epub 1994/07/01. PubMed PMID: 8018319.CrossRefGoogle Scholar
  5. 5.
    Chinn SB, Spector ME, Bellile EL, McHugh JB, Gernon TJ, Bradford CR, Wolf GT, Eisbruch A, Chepeha DB. Impact of perineural invasion in the pathologically N0 neck in oral cavity squamous cell carcinoma. Otolaryngol Head Neck Surg. 2013;149(6):893–9. Epub 2013/10/25. PubMed PMID: 24154744; PMCID: PMC4118458.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sparano A, Weinstein G, Chalian A, Yodul M, Weber R. Multivariate predictors of occult neck metastasis in early oral tongue cancer. Otolaryngol Head Neck Surg. 2004;131(4):472–6. Epub 2004/10/07. PubMed PMID: 15467620.CrossRefPubMedGoogle Scholar
  7. 7.
    D’Cruz AK, Vaish R, Kapre N, Dandekar M, Gupta S, Hawaldar R, Agarwal JP, Pantvaidya G, Chaukar D, Deshmukh A, Kane S, Arya S, Ghosh-Laskar S, Chaturvedi P, Pai P, Nair S, Nair D, Badwe R, Head and Neck Disease Management Group. Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med. 2015;373(6):521–9. Epub 2015/06/02. PubMed PMID: 26027881.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Goldstein DP, Ringash J, Bissada E, Jaquet Y, Irish J, Chepeha D, Davis AM. Evaluation of shoulder disability questionnaires used for the assessment of shoulder disability after neck dissection for head and neck cancer. Head Neck. 2014;36(10):1453–8. Epub 2013/09/03. PubMed PMID: 23996914.CrossRefPubMedGoogle Scholar
  9. 9.
    Goldstein DP, Ringash J, Bissada E, Jaquet Y, Irish J, Chepeha D, Davis AM. Scoping review of the literature on shoulder impairments and disability after neck dissection. Head Neck. 2014;36(2):299–308. Epub 2013/04/05. PubMed PMID: 23554002.CrossRefPubMedGoogle Scholar
  10. 10.
    Goldstein DP, Ringash J, Irish JC, Gilbert R, Gullane P, Brown D, Xu W, Del Bel R, Chepeha D, Davis AM. Assessment of the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire for use in patients after neck dissection for head and neck cancer. Head Neck. 2015;37(2):234–42. Epub 2014/01/01. PubMed PMID: 24375871.CrossRefPubMedGoogle Scholar
  11. 11.
    Chepeha DB, Taylor RJ, Chepeha JC, Teknos TN, Bradford CR, Sharma PK, Terrell JE, Wolf GT. Functional assessment using Constant’s Shoulder Scale after modified radical and selective neck dissection. Head Neck. 2002;24(5):432–6. Epub 2002/05/10. PubMed PMID: 12001072.CrossRefPubMedGoogle Scholar
  12. 12.
    Kuntz AL, Weymuller EA Jr. Impact of neck dissection on quality of life. Laryngoscope. 1999;109(8):1334–8. Epub 1999/08/12. PubMed PMID: 10443845.CrossRefPubMedGoogle Scholar
  13. 13.
    Gallagher KK, Sacco AG, Lee JS, Taylor R, Chanowski EJ, Bradford CR, Prince ME, Moyer JS, Wolf GT, Worden FP, Eisbruch A, Chepeha DB. Association between multimodality neck treatment and work and leisure impairment: a disease-specific measure to assess both impairment and rehabilitation after neck dissection. JAMA Otolaryngol Head Neck Surg. 2015;141(10):888–93. Epub 2015/10/02. PubMed PMID: 26426565.CrossRefPubMedGoogle Scholar
  14. 14.
    Erisen L, Basel B, Irdesel J, Zarifoglu M, Coskun H, Basut O, Tezel I, Hizalan I, Onart S. Shoulder function after accessory nerve-sparing neck dissections. Head Neck. 2004;26(11):967–71. Epub 2004/10/02. PubMed PMID: 15459926.CrossRefPubMedGoogle Scholar
  15. 15.
    Bradley PJ, Ferlito A, Silver CE, Takes RP, Woolgar JA, Strojan P, Suarez C, Coskun H, Zbaren P, Rinaldo A. Neck treatment and shoulder morbidity: still a challenge. Head Neck. 2011;33(7):1060–7. Epub 2010/10/21. PubMed PMID: 20960564.CrossRefPubMedGoogle Scholar
  16. 16.
    Taylor RJ, Chepeha JC, Teknos TN, Bradford CR, Sharma PK, Terrell JE, Hogikyan ND, Wolf GT, Chepeha DB. Development and validation of the neck dissection impairment index: a quality of life measure. Arch Otolaryngol Head Neck Surg. 2002;128(1):44–9. Epub 2002/01/12. PubMed PMID: 11784253.CrossRefGoogle Scholar
  17. 17.
    Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, Cochran A, Cormier JN, Gorman M, Kim TY, McMasters KM, Noyes RD, Schuchter LM, Valsecchi ME, Weaver DL, Lyman GH, American Society of Clinical O, Society of Surgical O. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 2012;30(23):2912–8. Epub 2012/07/11. PubMed PMID: 22778321; PMCID: PMC5950498.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Giammarile F, Alazraki N, Aarsvold JN, Audisio RA, Glass E, Grant SF, Kunikowska J, Leidenius M, Moncayo VM, Uren RF, Oyen WJ, Valdes Olmos RA, Vidal Sicart S. The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging. 2013;40(12):1932–47. Epub 2013/10/03. PubMed PMID: 24085499.CrossRefPubMedGoogle Scholar
  19. 19.
    (NCCN) NCCN. NCCN Clinical Practice Guidelines in Oncology: Cutaneous Melanoma (Version 1, 2019) 2018. Available from:
  20. 20.
    Network NCC. NCCN Guidelines for Breast Cancer (Version 3, 2018) 2018. Available from:
  21. 21.
    Prieto VG, Clark SH. Processing of sentinel lymph nodes for detection of metastatic melanoma. Ann Diagn Pathol. 2002;6(4):257–64. Epub 2002/08/10. PubMed PMID: 12170459.CrossRefGoogle Scholar
  22. 22.
    de Bree E, de Bree R. Implications of the MSLT-1 for sentinel lymph node biopsy in cutaneous head and neck melanoma. Oral Oncol. 2015;51(7):629–33. Epub 2015/05/06. PubMed PMID: 25936652.CrossRefPubMedGoogle Scholar
  23. 23.
    de Bree R, Takes RP, Castelijns JA, Medina JE, Stoeckli SJ, Mancuso AA, Hunt JL, Rodrigo JP, Triantafyllou A, Teymoortash A, Civantos FJ, Rinaldo A, Pitman KT, Hamoir M, Robbins KT, Silver CE, Hoekstra OS, Ferlito A. Advances in diagnostic modalities to detect occult lymph node metastases in head and neck squamous cell carcinoma. Head Neck. 2015;37(12):1829–39. PubMed PMID: 24954811.CrossRefPubMedGoogle Scholar
  24. 24.
    Alkureishi LW, Burak Z, Alvarez JA, Ballinger J, Bilde A, Britten AJ, Calabrese L, Chiesa C, Chiti A, de Bree R, Gray HW, Hunter K, Kovacs AF, Lassmann M, Leemans CR, Mamelle G, McGurk M, Mortensen J, Poli T, Shoaib T, Sloan P, Sorensen JA, Stoeckli SJ, Thomsen JB, Trifiro G, Werner J, Ross GL, European Association of Nuclear Medicine Oncology C, European Sentinel Node Biopsy Trial C. Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma. Ann Surg Oncol. 2009;16(11):3190–210. PubMed PMID: 19795174; PMCID: PMC2766455.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Alkureishi LW, Ross GL, Shoaib T, Soutar DS, Robertson AG, Thompson R, Hunter KD, Sorensen JA, Thomsen J, Krogdahl A, Alvarez J, Barbier L, Santamaria J, Poli T, Sesenna E, Kovacs AF, Grunwald F, Barzan L, Sulfaro S, Alberti F. Sentinel node biopsy in head and neck squamous cell cancer: 5-year follow-up of a European multicenter trial. Ann Surg Oncol. 2010;17(9):2459–64. PubMed PMID: 20552410.CrossRefPubMedGoogle Scholar
  26. 26.
    Civantos FJ, Zitsch RP, Schuller DE, Agrawal A, Smith RB, Nason R, Petruzelli G, Gourin CG, Wong RJ, Ferris RL, El Naggar A, Ridge JA, Paniello RC, Owzar K, McCall L, Chepeha DB, Yarbrough WG, Myers JN. Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1–T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. J Clin Oncol. 2010;28(8):1395–400. PubMed PMID: 20142602; PMCID: PMC2834497.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Broglie MA, Haerle SK, Huber GF, Haile SR, Stoeckli SJ. Occult metastases detected by sentinel node biopsy in patients with early oral and oropharyngeal squamous cell carcinomas: impact on survival. Head Neck. 2013;35(5):660–6. PubMed PMID: 22605675.CrossRefPubMedGoogle Scholar
  28. 28.
    Schilling C, Stoeckli SJ, Haerle SK, Broglie MA, Huber GF, Sorensen JA, Bakholdt V, Krogdahl A, von Buchwald C, Bilde A, Sebbesen LR, Odell E, Gurney B, O’Doherty M, de Bree R, Bloemena E, Flach GB, Villarreal PM, Fresno Forcelledo MF, Junquera Gutierrez LM, Amezaga JA, Barbier L, Santamaria-Zuazua J, Moreira A, Jacome M, Vigili MG, Rahimi S, Tartaglione G, Lawson G, Nollevaux MC, Grandi C, Donner D, Bragantini E, Dequanter D, Lothaire P, Poli T, Silini EM, Sesenna E, Dolivet G, Mastronicola R, Leroux A, Sassoon I, Sloan P, McGurk M. Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer. Eur J Cancer. 2015;51(18):2777–84. Epub 2015/11/26. PubMed PMID: 26597442.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Agrawal A, Civantos FJ, Brumund KT, Chepeha DB, Hall NC, Carroll WR, Smith RB, Zitsch RP, Lee WT, Shnayder Y, Cognetti DM, Pitman KT, King DW, Christman LA, Lai SY. [(99m)Tc]Tilmanocept accurately detects sentinel lymph nodes and predicts node pathology status in patients with oral squamous cell carcinoma of the head and neck: results of a phase III multi-institutional trial. Ann Surg Oncol. 2015;22(11):3708–15. PubMed PMID: 25670018; PMCID: PMC4565859.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Flach GB, Bloemena E, Klop WM, van Es RJ, Schepman KP, Hoekstra OS, Castelijns JA, Leemans CR, de Bree R. Sentinel lymph node biopsy in clinically N0 T1–T2 staged oral cancer: the Dutch multicenter trial. Oral Oncol. 2014;50(10):1020–4. Epub 2014/08/29. PubMed PMID: 25164950.CrossRefPubMedGoogle Scholar
  31. 31.
    Liu M, Wang SJ, Yang X, Peng H. Diagnostic efficacy of sentinel lymph node biopsy in early oral squamous cell carcinoma: a meta-analysis of 66 studies. PLoS One. 2017;12(1):e0170322. Epub 2017/01/21. PubMed PMID: 28107500; PMCID: PMC5249063.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Govers TM, Hannink G, Merkx MA, Takes RP, Rovers MM. Sentinel node biopsy for squamous cell carcinoma of the oral cavity and oropharynx: a diagnostic meta-analysis. Oral Oncol. 2013;49(8):726–32. Epub 2013/05/18. PubMed PMID: 23680537.CrossRefGoogle Scholar
  33. 33.
    Thompson CF, St John MA, Lawson G, Grogan T, Elashoff D, Mendelsohn AH. Diagnostic value of sentinel lymph node biopsy in head and neck cancer: a meta-analysis. Eur Arch Otorhinolaryngol. 2013;270(7):2115–22. PubMed PMID: 23263205; PMCID: 4167685.CrossRefPubMedGoogle Scholar
  34. 34.
    Bonnardot L, Bardet E, Steichen O, Cassagnau E, Piot B, Salam AP, Campion L, Ferron C, Beauvillain de Montreuil C, Malard O. Prognostic factors for T1–T2 squamous cell carcinomas of the mobile tongue: a retrospective cohort study. Head Neck. 2011;33(7):928–34. Epub 2011/06/16. PubMed PMID: 21674667.CrossRefPubMedGoogle Scholar
  35. 35.
    Kelner N, Vartanian JG, Pinto CA, Coutinho-Camillo CM, Kowalski LP. Does elective neck dissection in T1/T2 carcinoma of the oral tongue and floor of the mouth influence recurrence and survival rates? Br J Oral Maxillofac Surg. 2014;52(7):590–7. Epub 2014/05/21. PubMed PMID: 24840539.CrossRefPubMedGoogle Scholar
  36. 36.
    Yuen AP, Ho CM, Chow TL, Tang LC, Cheung WY, Ng RW, Wei WI, Kong CK, Book KS, Yuen WC, Lam AK, Yuen NW, Trendell-Smith NJ, Chan YW, Wong BY, Li GK, Ho AC, Ho WK, Wong SY, Yao TJ. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head Neck. 2009;31(6):765–72. PubMed PMID: 19408291.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Cramer JD, Sridharan S, Ferris RL, Duvvuri U, Samant S. Sentinel lymph node biopsy versus elective neck dissection for stage I to II oral cavity cancer. Laryngoscope. 2018. . Epub 2018/10/05. PubMed PMID: 30284248.
  38. 38.
    Schiefke F, Akdemir M, Weber A, Akdemir D, Singer S, Frerich B. Function, postoperative morbidity, and quality of life after cervical sentinel node biopsy and after selective neck dissection. Head Neck. 2009;31(4):503–12. Epub 2009/01/22. PubMed PMID: 19156833.CrossRefPubMedGoogle Scholar
  39. 39.
    Govers TM, Schreuder WH, Klop WM, Grutters JP, Rovers MM, Merkx MA, Takes RP. Quality of life after different procedures for regional control in oral cancer patients: cross-sectional survey. Clin Otolaryngol. 2016;41(3):228–33. Epub 2015/07/23. PubMed PMID: 26198548.CrossRefPubMedGoogle Scholar
  40. 40.
    Murer K, Huber GF, Haile SR, Stoeckli SJ. Comparison of morbidity between sentinel node biopsy and elective neck dissection for treatment of the n0 neck in patients with oral squamous cell carcinoma. Head Neck. 2011;33(9):1260–4. Epub 2011/08/13. PubMed PMID: 21837694.CrossRefPubMedGoogle Scholar
  41. 41.
    Haerle SK, Soyka MB, Fischer DR, Murer K, Strobel K, Huber GF, Holzmann D. The value of 18F-FDG-PET/CT imaging for sinonasal malignant melanoma. Eur Arch Otorhinolaryngol. 2012;269(1):127–33. Epub 2011/06/30. PubMed PMID: 21713453.CrossRefPubMedGoogle Scholar
  42. 42.
    Hernando J, Villarreal P, Alvarez-Marcos F, Gallego L, Garcia-Consuegra L, Junquera L. Comparison of related complications: sentinel node biopsy versus elective neck dissection. Int J Oral Maxillofac Surg. 2014;43(11):1307–12. Epub 2014/08/17. PubMed PMID: 25128262.CrossRefPubMedGoogle Scholar
  43. 43.
    van der Linden N, Flach GB, de Bree R, Uyl-de Groot CA. Cost-utility of sentinel lymph node biopsy in cT1–T2N0 oral cancer. Oral Oncol. 2016;53:20–6. Epub 2015/12/04. PubMed PMID: 26631953.CrossRefPubMedGoogle Scholar
  44. 44.
    Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392–9. Epub 1992/04/01. PubMed PMID: 1558490.CrossRefGoogle Scholar
  45. 45.
    Albo D, Wayne JD, Hunt KK, Rahlfs TF, Singletary SE, Ames FC, Feig BW, Ross MI, Kuerer HM. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg. 2001;182(4):393–8. Epub 2001/11/27. PubMed PMID: 11720678.CrossRefGoogle Scholar
  46. 46.
    Tripathy S, Nair PV. Adverse drug reaction, patent blue V dye and anaesthesia. Indian J Anaesth. 2012;56(6):563–6. Epub 2013/01/18. PubMed PMID: 23325942; PMCID: PMC3546244.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Baker JL, Pu M, Tokin CA, Hoh CK, Vera DR, Messer K, Wallace AM. Comparison of [(99m)Tc]tilmanocept and filtered [(99m)Tc]sulfur colloid for identification of SLNs in breast cancer patients. Ann Surg Oncol. 2015;22(1):40–5. Epub 2014/07/30. PubMed PMID: 25069859; PMCID: PMC4273083.CrossRefPubMedGoogle Scholar
  48. 48.
    Unkart JT, Hosseini A, Wallace AM. Tc-99m tilmanocept versus Tc-99m sulfur colloid in breast cancer sentinel lymph node identification: Results from a randomized, blinded clinical trial. J Surg Oncol. 2017;116(7):819–23. Epub 2017/07/12. PubMed PMID: 28695567.CrossRefPubMedGoogle Scholar
  49. 49.
    Wallace AM, Han LK, Povoski SP, Deck K, Schneebaum S, Hall NC, Hoh CK, Limmer KK, Krontiras H, Frazier TG, Cox C, Avisar E, Faries M, King DW, Christman L, Vera DR. Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials. Ann Surg Oncol. 2013;20(8):2590–9. Epub 2013/03/19. PubMed PMID: 23504141; PMCID: PMC3705144.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Chaturvedi P, Datta S, Arya S, Rangarajan V, Kane SV, Nair D, Nair S, Chaukar DA, Pai PS, Pantvaidya G, Deshmukh AD, Agrawal A, D'Cruz AK. Prospective study of ultrasound-guided fine-needle aspiration cytology and sentinel node biopsy in the staging of clinically negative T1 and T2 oral cancer. Head Neck. 2015;37(10):1504–8. Epub 2014/06/04. PubMed PMID: 24890924.CrossRefPubMedGoogle Scholar
  51. 51.
    Schmalbach CE, Nussenbaum B, Rees RS, Schwartz J, Johnson TM, Bradford CR. Reliability of sentinel lymph node mapping with biopsy for head and neck cutaneous melanoma. Arch Otolaryngol Head Neck Surg. 2003;129(1):61–5. Epub 2003/01/15. PubMed PMID: 12525196.CrossRefGoogle Scholar
  52. 52.
    Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, Roses DF, Karakousis CP, Mozzillo N, Reintgen D, Wang HJ, Glass EC, Cochran AJ. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg. 1999;230(4):453–63, discussion 63–5. Epub 1999/10/16. PubMed PMID: 10522715; PMCID: PMC1420894.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Otolaryngology—Head and Neck Surgery, Michigan MedicineUniversity of MichiganAnn ArborUSA
  2. 2.Department of Head and Neck SurgeryThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Department of Molecular and Cellular OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  4. 4.Department of Radiation OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations